On Monday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Union Pacific (NYSE:UNP), Halozyme Therapeutics, (NASDAQ:HALO), bluebird bio (NASDAQ:BLUE), California Resources (NYSE:CRC)

Union Pacific Corporation (NYSE:UNP) declined -3.98%, and closed at $112.78. The company has the market capitalization of $103.51 billion. The beta value of the stock is 0.90. On the other hand the stock’s volatility for the week is 1.89%, and for the month is 1.48%. The stock’s price to book ratio is $4.71, however price to sale ratio is $4.14. Analyst’s mean recommendation regarding this stock is 1.90. (Where 1=Buy, 5=Sale).

Union Pacific Corporation (UNP) through its subsidiary, Union Pacific Railroad Company, operates railroads in the United States. The company offers freight transportation services for agricultural products, including grains, commodities produced from grains, and food and beverage products; automotive products, such as finished vehicles and automotive parts; and chemicals consisting of industrial chemicals, plastics, crude oil, liquid petroleum gases, fertilizers, soda ash, sodium products, and phosphorus rock and sulfur products.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) decreased -3.96%, and closed at $14.05. The stock has price to sale ratio of 23.64, however, price to book ratio is 42.58. With recent decline, the year-to-date (YTD) performance reflected a 49.47% incline above last year. During the past month the stock lose -9.47%, bringing three-month performance to 55.59% and six-month performance to 43.81%. The mean recommendation of analysts for this stock is 2.30 (where 1=Buy, 5=Sale).

Halozyme Therapeutics, Inc. (HALO) a biotechnology company, researches, develops, and commercializes human enzymes. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit.

bluebird bio Inc (NASDAQ:BLUE) decreased -3.82%, and closed at $119.99. The company holds the market capitalization of $4.06B. For the last twelve months, the stock was able to keep return on equity at -18.30%, while return on assets at –14.50%, in response to its return on investment at -9.90%. Its 20-day moving average gained 8.86%, Above50-day moving average of 19.62%, above 200-day moving average of 107.52% from the latest market price of $119.99. The mean recommendation of analysts for this stock is 1.70. (Where 1=Buy, 5=Sale).

bluebird bio Inc (BLUE) a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD.

California Resources Corp (NYSE:CRC) fell -3.79%, and closed at $7.11.Its volatility for the week is 7.31%, while for the month it is 6.19%. The company has the market capitalization of $2.85 million. The company holds the book value per share of 6.84, whereas cash per share is 0.04. Price to book ratio remained 1.04, while price to sale ratio is 0.66.

California Resources Corp (CRC) Corporation operates as an oil and natural gas exploration and production company in the State of California. It produces oil, natural gas, and natural gas liquids. The company holds interests in approximately 2.4 million net acres. It also gathers, processes, and markets oil and gas products, as well as produces and sells power. The company is headquartered in Los Angeles, California.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.